Alimta package insert

Alimta [package insert]. Indianapolis, IN; Eli Lilly; January 2024. Accessed April 2024. 2. Referenced with permission from the NCCN Drugs

Alimta (pemetrexed) Intravenous. POLICY NUMBER. LAST REVIEW Alimta [package insert]. Indianapolis, IN; Eli Lilly; January 2024

12 Alimta Product Package Insert. Eli Lilly and Company. Indianapolis, Indiana. August 2024. 13 Niyikiza C. baker SD, Seitz DE, Walling JM

Brief patient counseling information can be found in the Pemetrexed (Alimta) package insert

Alimta 500 mg powder for injection; single-use vial: xx Pemfexy 500 mg/20 mL solution for injection, single-use vial: xx VII. References 1. Alimta [package insert]. Indianapolis, IN; Eli Lilly; January 2024. Accessed July 2024. 2. Pemfexy [package insert]. Woodcliff Lake, NJ; Eagle Pharmaceuticals, Inc; February 2024.

by Z Schlei 2024 Cited by 8Pemetrexed (Alimta) is a folate analog metabolic inhibitor that disrupts Following these results, the final FDA-approved package insert for pemetrexed

package insert for specific dosing advice). ALIMTA as single agent: In patients treated for non-small cell lung cancer after prior chemotherapy, the recommended dose of ALIMTA is 500 mg/m2 BSA administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle. Premedication regimen:

See cisplatin package insert for more information. The recommended dose of ALIMTA is 500 mg/m2 administered as an intravenous infusion over 10 minutes on Day 1

Alimta [package insert]. Indianapolis, IN; Eli Lilly; May 2024. Accessed November 2024. 2. Pemfexy [package insert]. Woodcliff Lake, NJ